12.50
12.50 (0.51%)
As of Jan 09, 2024
Point Biopharma Global Inc. [PNT]
Source:
Company Overview
POINT Biopharma Global Inc. is a next-generation radioligand company. Our mission is to accelerate the discovery, development and global access to targeted radioligand therapies.
| Country | United States |
| Headquarters | indianapolis, indiana |
| Phone Number | (317) 543-9957 |
| Industry | |
| CEO | Joe Mccann |
| Website | www.pointbiopharma.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $2.8 |
| Operating Profit | $-29.6 |
| Net Income | $-24.8 |
| Net Cash | $-264.8 |
Profit Ratios
| Gross Margin | |
| Operating Margin | -1,061.9 |
| Profit as % of Revenues | |
| Profit as % of Assets | -4.7% |
| Profit as % of Stockholder Equity | -5.8% |
Management Effectiveness
| Return on Equity | -5.8% |
| Return on Assets | -5.2% |
| Turnover Ratio | 0% |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | $477.7 |
| Total Liabilities | $53.5 |
| Operating Cash Flow | $-124.9 |
| Investing Cash Flow | $-140 |
| Financing Cash Flow | $0 |
